

Latham Counsels Merrill Lynch as Advisor to AstraZeneca in Acquisition of MedImmune

AstraZeneca PLC, one of the world's leading pharmaceutical companies, announced it will acquire MedImmune, Inc., a world-leading biotechnology company, in an all-cash transaction valued at \$15.6 billion. The combined entity will create a leading, fully-integrated biotechnology business within AstraZeneca with critical mass in research, development, regulatory and manufacturing with global sales reach. The deal is expected to close in June 2007. Latham & Watkins LLP represents Merrill Lynch which is acting as financial advisor to AstraZeneca in this transaction. The Latham mergers and acquisitions team is led by New York corporate partner Charles Nathan and Orange County corporate partner Charles Ruck working with New York associate Constantine (Costa) Skarvelis.

For more information please contact Charles Nathan at (212) 906-1730 or Charles Ruck at (714) 755-8245.